Illumina, Agilent in Resequencing Co-marketing Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina and Agilent have entered into a non-exclusive co-marketing agreement focused on researchers conducting targeted resequencing.

The firms jointly announced today that they will co-market Agilent's SureSelect Target Enrichment System with Illumina's Genome Analyzer. They said the combination will provide researchers with a method for efficiently resequencing specific regions of interest in the genome and will enable researchers to conduct studies that otherwise would not be feasible.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.